Q
Quotient Clinical
Accelerated drug development, manufacturing, and clinical trial services
About Quotient Clinical
In 1990, two separate but complementary UK-based companies were founded: Pharmaceutical Profiles, a spin-out from the University of Nottingham, and Quotient Bioresearch, a contract research organization (CRO). These entities would later form the foundation of a business focused on expediting early-stage drug development. The key idea was to integrate services that were typically siloed, saving pharmaceutical clients precious time and money. In 2009, a pivotal moment occurred when Quotient Bioresearch acquired the Edinburgh clinical research facility from Charles River Laboratories and combined it with Pharmaceutical Profiles to create a new entity: Quotient Clinical. This new company centered its operations around an innovative platform called Translational Pharmaceutics®. This approach uniquely integrated drug formulation, real-time manufacturing, and clinical testing all within a single organization, significantly streamlining the development process. A series of acquisitions fueled further growth. In 2015, GHO Capital acquired the company, providing support for expansion. This was followed by key acquisitions in the US, including SeaView Research and QS Pharma in 2017, establishing a crucial American footprint. Reflecting its expanded global reach and broader service portfolio, Quotient Clinical rebranded to Quotient Sciences in November 2017. The growth trajectory continued with the 2019 majority stake acquisition by global investment firm Permira, which funded further expansion, including the 2021 purchase of Arcinova, a UK-based CDMO.
Source: Dealroom company dataNews
Open roles
Quotient Clinical in the Colchester ecosystem
The Quotient Clinical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
TA Associates
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quotient Clinical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quotient Clinical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

